Professor Lee Yong Lim
Medicine and Pharmacology, School of, Pharmacology, Pharmacy and Anaesthesiology Unit
- Contact details
- School of Medicine and Pharmacology - Pharmacology, Pharmacy and Anaesthesiology Unit
The University of Western Australia (M315)
35 Stirling Highway
CRAWLEY WA 6009
- +61 8 6488 4413
- +61 8 6488 7532
- Personal homepage
- Room 2.06A, Curnow Building, Crawley campus
- BSc(Pharm) Sing., PhD Manc.
- Professor Lee Yong Lim completed her Bachelor of Science with honours in pharmacy at the National University of Singapore. She did her PhD at the University of Manchester in the United Kingdom before returning to the National University of Singapore to work in the Pharmacy Department. Professor Lim moved to UWA in 2005.
- Key research
- My laboratory is currently focusing on research to understand the constraints of administering medicines to children, and to develop palatable, age-appropriate medicines to meet those needs. Current projects include:
- (1)Development and evaluation of chocolate-based solid medicinal formulations, which has now reached the clinical stage of evaluation.
- (2)Development and evaluation of milk-based solid medicinal formulations
- (3)Reformulating available medicines which present with stability issues under simulated conditions of use in paediatric patients.
- (4)Establishing what constitute age-appropriate dosage forms for children of different age groups through the involvement of children, caregivers and health care professionals.
- (5)Working with caregivers to understand the methods and difficulties of achieving medication compliance in children in the home environment.
- (6)Establishing a platform for children and caregivers to participate in, and to be influencers of clinical trials involving children.
- My laboratory is also known for using nanotechnology to develop drug delivery systems, including polymer nanoparticles, liposomes and plant viral protein cages, some with targeting capability for the delivery of chemotherapeutic agents to cancer cells. The expertise gained from nanotechnology is applied now to also develop palatable and age-appropriate medicines to meet the needs of paediatric patients.
- J Mo, PK Eggers, CL Raston, LY Lim, Development and validation of a LC/TOF MS method for the determination of carboplatin and paclitaxel in nanovesicles, Analytical and Bioanalytical Chemistry, 406 (2014): 2659 - 2667.
J Mo, LY Lim (co-corresponding author), Z Zhang, L-carnitine ester of prednisolone: pharmacokinetic and pharmacodynamic evaluation of a Type 1 prodrug, International Journal of Pharmaceutics, 475 (2014): 123 - 129.
K Huanbutta, P Sriamornsak, M Luangtana-anan, S Limmatvapirat, S Puttipipatkhachorn, L Y Lim, K Terada, J Nunthanid, Application of multiple stepwise spinning disk processing for the synthesis of poly(methyl acrylates) coated chitosan-diclofenac sodium nanoparticles for colonic drug delivery, European Journal of Pharmaceutical Sciences, 50 (2013): 303-311.
Shigdar S, L Qiao, S Zhou, D Xiang, T Wang, Y Li, LY Lim, L Kong, L Li, W Duan, RNA aptamers targeting cancer stem cell marker CD133, Cancer Letters, 330 (2013): 84-95.
Loh JW, M Saunders, LY Lim, Cytotoxicity of monodispersed chitosan nanoparticles against the Caco-2 cells, Toxicology and Applied Pharmacology, 262 (2012): 273-282.
Weeden C, KJ Hartlieb, LY Lim, Preparation and physicochemical characterization of a novel paclitaxel-loaded amphiphilic aminocalixarene nanoparticle platform for anticancer chemotherapy, Journal of Pharmacy and Pharmacology, accepted 2012
Khor E, H Wu, LY Lim, CM Guo, Chitin methacrylate: preparation, characterization and hydrogel formation, Materials, 4: pp 1728-1746 (2011)
Loh JW, G Yeoh, M Saunders, LY Lim, Uptake and cytotoxicity of chitosan nanoparticles in human liver cells, Toxicology and Applied Pharmacology, 249: pp 148–157 (2010)
Wang CX, PCL Ho, LY Lim, Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells, International Journal of Pharmaceutics, 400: pp 201–210 (2010)
Ren YP, SM Wong, LY Lim, Application of Plant Viruses as Nano Drug Delivery Systems, Pharmaceutical Research, 27: pp 2509–2513 (2010)
Loh JW, J Schneider, M Carter, M Saunders, LY Lim, Spinning disc processing technology: potential for large-scale manufacture of chitosan nanoparticles, Journal of Pharmaceutical Sciences, 99: pp 4326 – 4336 (2010)
Cheng WQ, LY Lim, Design, synthesis, characterization and in vivo activity of a novel salmon calcitonin conjugate containing a novel PEG-lipid moiety. Journal of Pharmacy and Pharmacology. 62: pp 296–304 (2010)
Zhang W, Y Han, SL Lim, LY Lim, Dietary regulation of P-gp function and expression, Expert Opinion On Drug Metabolism and Toxicology, 5: pp 789 – 801 (2009)
Cheng WQ, LY Lim, Lipeo-sCT: a novel reversible lipidized salmon calcitonin derivative, its biophysical properties and hypocalcemic activity. European Journal of Pharmaceutical Sciences, 37: pp 151 – 159 (2009)
Cheng, W.Q., Lim, L.Y. Synthesis, characterization and in vivo activity of salmon calcitonin co-conjugated with lipid and polyethylene glycol, Journal of Pharmaceutical Sciences, 98: pp 1438 – 1451 (2009)
Zhang, W., Lim, L.Y. Effects of spice constituents on P-gp-mediated transport and CYP3A4-mediated metabolism in vitro, Drug Metabolism and Disease, 36: pp 1283-1290 (2008)
Cheng, W.Q., Lim, L.Y. Comparison of reversible and non-reversible aqueous soluble lipidized conjugates of salmon calcitonin, Molecular Pharmaceutics, 5: pp 610-621 (2008)
Han, Y., Tan, T.M.C., Lim, L.Y. In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression, Toxicology and Applied Pharmacology, 230: pp 283-289 (2008)
Cheng, W.Q., Lim, L.Y. Peroral delivery of peptide drugs, American Pharmaceutical Review, 11: pp 33-41 (2008)
Cheng, W.Q., Jois, S.D.S., Lim, L.Y. Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity, Pharmaceutical Research, 24: pp 99-101 (2007)
Zhang, W., Tan, T.M.C., Lim, L.Y. Impact of curcumin-induced changes in P-gp and CYP3A expression on the pharmacokinetics of the peroral celiprolol and midazolam in rats, Drug Metabolism and Disposition, 35: pp 110-115 (2007)
Ren, Y.P., Wong, S.M., Lim, L.Y. Folic-acid conjugated protein cages of a plant virus: a novel delivery platform for doxorubicin, Bioconjugate Chemistry, 18: pp 836-843 (2007)
Ren, Y.P., Wong, S.M., Lim, L.Y. In vitro reassembled plant virus-like particles for loading of polyacids, Journal of General Virology, 87: pp 2749 – 2754 (2006)
Han, Y., Tan, T.M.C., Lim, L.Y. Effects of capsaicin on P-gp function and expression in Caco-2 Cells, Biochemical Pharmacology, 71: pp 1727 – 1734 (2006)
Lim, S.L., Lim, L.Y. Effects of citrus fruit juices on cytotoxicity and drug transport pathways of Caco-2 cell monolayers, International Journal of Pharmaceutics, 307: pp 42 – 50 (2006)
Mo, Y., Lim, L.Y. Paclitaxel-loaded PLGA nanoparticles: Potentiation of anticancer activity by surface conjugation with wheat germ agglutinin, Journal of Controlled Release, 108: pp 244 – 262 (2005)
Mo, Y., Lim, L.Y. Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate, Journal of Controlled Release, 107: pp 30 – 42 (2005)
Luangtana-anan, M., Opanasopit, P., Ngawhirunpat, T., Nunthanid, J., Sriamornsak, P., Limmatvapirat, S., Lim, L.Y. Effect of chitosan salts and molecular weight on a nanoparticulate carrier for therapeutic protein, Pharmaceutical Development and Technology, 10: 189 – 196 (2005)
Huang, M., Fong, C.W., Khor, E., Lim, L.Y. Transfection efficiency of chitosan vectors: effect of polymer molecular weight and degree of deacetylation, Journal of Controlled Release, 106: pp 391 – 406 (2005)
Ma, Z.S., Lim, T.M., Lim, L.Y. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats, International Journal of Pharmaceutics, 293: pp 271 – 280 (2005)
Zhou, S., Chan, E., Lim, L.Y., Boelsterli, U.A., Li, S.C., Wang, J., Zhang, Q., Huang, M., Xu, A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4, Current Drug Metabolism, 5: pp 415 – 442 (2004)
Nealda Leila, M.Y., Lim, L.Y., Khor, E. Flexible chitin films: structural studies, Carbohydrate Research, 339: pp 2701-11 (2004)
Nunthanid, J., Luangtana-anan, M., Sriamornsak, P., Limmatvapirat, S., Puttipipatkhachorn, S., Lim, L.Y., Khor, E. Characterization of chitosan acetate as a binder for sustained release tablets, Journal of Controlled Release, 99: pp 15-26 (2004)
Cheng, W.Q., Lim, L.Y. Insulin-loaded calcium pectinate nanoparticles: effects of pectin molecular weight and formulation pH, Drug Development and Industrial Pharmacy, 30: pp 359-367 (2004)
Huang, M., Khor, E., Lim, L.Y. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation, Pharmaceutical Research, 21: pp 344-353 (2004)
Zhou, S., Lim, L.Y. Chowbay, B. Herbal modulation of P-glycoprotein, Drug Metabolism Reviews, 36: pp 1-48 (2004)
Ge, Z., Baguenard, A.S., Lim, L.Y., Wee, A., Khor, E. Hydroxyapatite-chitin materials as potential tissue engineered bone substitute, Biomaterials, 25: pp 1049-1058 (2004)
Mo, Y., Lim, L.Y. Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells, Journal of Pharmaceutical Sciences, 93: pp 20-28 (2004)
- Funding received
- 1.Development and clinical evaluation of palatable chocolate-based drug formulations to achieve optimised health outcomes for paediatric population, Princess Margaret Hospital Foundation New Investigator Project Grant 2014, Laurence Cheung, LY Lim, Britta Regli-von Ungern Sternberg, Aug 2014 – Feb 2016, $79,909.
Phosphonated calixarenes for the targeted intracellular delivery of anticancer agents, $311,175, Jan 2012 – Dec 2014, LY Lim, CL Raston, National Health and Medical Research Council, Australia, APP1028339
Calixarenes - tuneable nanoscale platforms for targeted delivery of anticancer drugs, $140,000, Jan 2008 – Dec 2010, LY Lim, M Makha, Cancer Council of Western Australia.
In vitro cytotoxicity of chitosan nanoparticles prepared by spinning disc reactor technology, $6,000, 2005, UWA small grants.
Anti-tumour mechanisms of action and prophylactic activity of tea tree oil, PRJ-005131, M Beilharz, TV Riley, SJ Greay, DJ Ireland, PH Hart, LY Lim, CF Carson, Rural Industries Research and Development Corporation, 1/8/10 – 30/9/12, $377,128.
Nanotechnology for Healthcare, M de Planque, C Backhouse, LY Lim, C Wälti, Worldwide Universities Network Research Development Fund, 2010, £17,600.
Nuclear Magnetic Resonance Microimaging and Relaxometry Facility (LE0989788), TG St Pierre, RN Martins, SM Smith, SJ Berners-Price, SA Dunlop, AR Harvey, CL Raston, D Robertson, GC Yeoh, BA Corry, L Fitzgerald, MJ House, GA Koutsantonis, LY Lim, M Makha, D Meyrick, G Plant, J Rodger, M Ruitenberg, KL Swaminatha-Iyer, G Verdile, VP Wallace, RC Woodward, 2008, $108,481, Australian Research Council, LIEF funding.
Targeted process development for drug delivery (LP0883914), Raston CL, Swaminatha-Iyer KL, Lim LY, Bosch B, 2008, A$297,364, Australian Research Council Linkage funding with iCeutica.
Integrated Process Intensification Facility (LE0882634), Raston, Pareek, Bond, Burcham, Chua, Flematti, Gao, Swaminatha-Iyer, Lim, Makha, Norret, Polomska, P Price, I Price, St Pierre, Stewart, Wild, Yeoh, Bakker, Brown, De Marco, Gale, Li, Lou, Tade, Wang, Wright, 2008, A$220,000, Australia Research Council, LIEF funding.
Cellular and molecular modulation of drug transport by common spices in the South East Asian diet, $326,150, July 2002 to June 2005, Biomedical Research Council, Singapore.
Wound dressings with sustained antimicrobial capability, $50,000, Mar 1997 – Mar 1999, Defence Science Organisation (co-CI)
Survey on consumer assessment of novel tablet formulation, $5,000, May 1998 – Sept 1998, Merck Sharp & Dohme (I.A.) Corporation, Singapore.
Nano-systems to facilitate site-specific drug delivery and enhance cellular drug uptake, $116,500, Apr 2003 – Mar 2006, NUS Academic Fund.
Dietary modulation of drug transport, $124,900, Nov 2001 – Oct 2004, NUS Academic Fund.
Polymer nanospheres for drug delivery, $123,300, Feb 2000 – Jan 2003, NUS Academic Fund.
Chitosan-Alginate Membranes, $82,700, Jan 1999 – Dec 2001, NUS Academic Fund.
Drug Information Centres, $6,500, Jul 1996 – Aug 1998, NUS Academic Fund.
Effects of sterilization on chitosan and chitosan-based drug delivery systems, $153,500, Apr 1996 – Mar 1999, NUS Academic Fund.
Development of novel injectable bone substitute material, $76,000, May 2004 to April 2007, co-CI, NUS Academic Fund.
Chitin-hydroxyapatite materials as bone substitutes, $59,180, Jul 2000 – Jun 2003, co-CI, NUS Academic Fund.
Packaging enzymes for cyanogens analysis, $79,600, Jan 1999 – Dec 2000, co-CI, NUS Academic Fund.
Design and development of transdermal therapeutic systems for peri-operative applications, $175,866, Apr 1997 – Mar 2001, co-CI, NUS Academic Fund.
The development of chitin based materials for tissue engineering, $391,300, Dec 1996 – Jul 2000, co-CI, NUS Academic Fund.
Interaction of halofantrine with phospholipids vesicles, $12,700, Feb 1996 – Feb 1999, co-CI, NUS Academic Fund.
Stability studies of extemporaneously prepared formulations used in hospitals, $86,800, Dec 1994 – Dec 1997, co-CI, NUS Academic Fund.
Water-soluble polymer carriers to deliver pharmaceuticals and chemicals, $24,000, Apr 1992 – Apr 1995, co-CI, NUS Academic Fund.
- Controlled Release Society
American Association of Pharmaceutical Scientists
Australian Research Council Nanotechnology Network
UWA Centre for Strategic Nanofabrication
- Honours and awards
- Pharmacy Teaching Award, Faculty of Science, National University of Singapore- 1995, 1996, 2005
Excellent Teacher Award, National University of Singapore- 2004
Teaching Excellence Award, Faculty of Science, National University of Singapore- 1997, 2002, 2004, 2005
Meritorious Teaching Award, Faculty of Science, National University of Singapore- 1999, 2000
Science Teaching Award, Faculty of Science, National University of Singapore 1997
- A Bone and/or Dental Cement Composition and Uses Thereof, WO 2009/029049, 5 March 2009, Eugene Khor, Chang Ming Guo, Hong Wu, Lee Yong Lim.
- Professor Lim is Unit Co-ordinator for the following subjects:
PHCY8610 Physical Pharmacy and Biopharmaceutics
PHCY5611 Medicinal Product Formulation
PHCY5614 Pharmacy Research Project
PHCY5617 Clinical Science for Pharmacy II
PHCY3301 Therapeutic Product Formulation
She delivers lectures for PHCY8610 Pharmaceutics, PHCY3301 Therapeutic Product Formulation and PHCY8609 Current Developments in Nutrition, Health and Biotechnology, and conducts extemporaneous compounding practical classes for PHCY8610 Pharmaceutics and PHCY8603 Pharmacotherapy and Medication Review.
- Research profile
Research profile and publications